Nuveen LLC Takes $2.69 Million Position in Cardiff Oncology, Inc. $CRDF

Nuveen LLC acquired a new position in Cardiff Oncology, Inc. (NASDAQ:CRDF) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 857,570 shares of the company’s stock, valued at approximately $2,693,000. Nuveen LLC owned about 1.29% of Cardiff Oncology as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the company. Dauntless Investment Group LLC acquired a new stake in shares of Cardiff Oncology in the 1st quarter valued at $302,000. Nuveen Asset Management LLC grew its position in shares of Cardiff Oncology by 73.7% in the 4th quarter. Nuveen Asset Management LLC now owns 586,616 shares of the company’s stock valued at $2,546,000 after buying an additional 248,850 shares during the last quarter. Laurion Capital Management LP purchased a new position in Cardiff Oncology during the 4th quarter worth approximately $2,504,000. Northern Trust Corp grew its stake in Cardiff Oncology by 8.9% during the 4th quarter. Northern Trust Corp now owns 337,092 shares of the company’s stock worth $1,463,000 after buying an additional 27,489 shares during the last quarter. Finally, Millennium Management LLC grew its position in Cardiff Oncology by 188.8% during the 4th quarter. Millennium Management LLC now owns 440,944 shares of the company’s stock worth $1,914,000 after purchasing an additional 288,259 shares during the last quarter. Institutional investors and hedge funds own 16.29% of the company’s stock.

Insiders Place Their Bets

In related news, Director Gary W. Pace purchased 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 30th. The stock was acquired at an average price of $2.45 per share, for a total transaction of $36,750.00. Following the transaction, the director directly owned 1,345,676 shares of the company’s stock, valued at $3,296,906.20. This trade represents a 1.13% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 7.70% of the company’s stock.

Cardiff Oncology Stock Down 4.1%

CRDF stock opened at $2.08 on Friday. The stock’s 50 day moving average is $3.14 and its two-hundred day moving average is $3.30. The company has a market capitalization of $138.37 million, a PE ratio of -2.39 and a beta of 1.54. Cardiff Oncology, Inc. has a 52-week low of $2.08 and a 52-week high of $5.64.

Cardiff Oncology (NASDAQ:CRDF) last announced its quarterly earnings data on Tuesday, July 29th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). Cardiff Oncology had a negative net margin of 9,344.14% and a negative return on equity of 77.94%. The business had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.11 million. As a group, sell-side analysts anticipate that Cardiff Oncology, Inc. will post -0.99 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on CRDF. William Blair reiterated an “outperform” rating on shares of Cardiff Oncology in a research note on Wednesday, June 18th. LADENBURG THALM/SH SH started coverage on shares of Cardiff Oncology in a report on Tuesday, July 8th. They set a “buy” rating and a $19.00 price objective on the stock. Jefferies Financial Group initiated coverage on Cardiff Oncology in a research report on Tuesday, June 24th. They set a “hold” rating and a $3.50 target price on the stock. Finally, HC Wainwright reduced their price objective on Cardiff Oncology from $18.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, August 6th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Cardiff Oncology has an average rating of “Moderate Buy” and a consensus target price of $10.10.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.